These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 16477567)
1. Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials. Raffi F; Katlama C; Saag M; Wilkinson M; Chung J; Smiley L; Salgo M Clin Infect Dis; 2006 Mar; 42(6):870-7. PubMed ID: 16477567 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M; N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645 [TBL] [Abstract][Full Text] [Related]
3. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M; N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625 [TBL] [Abstract][Full Text] [Related]
4. A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide. Beatty G; Hunt P; Smith A; Hoh R; Huang W; Martin J; Deeks SG Antivir Ther; 2006; 11(3):315-9. PubMed ID: 16759047 [TBL] [Abstract][Full Text] [Related]
5. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice. Bienvenu B; Krivine A; Rollot F; Pietri MP; Lebault V; Meritet JF; Guerin C; Spiridon G; Salmon D; Guillevin L; Lebon P; Launay O J Med Virol; 2006 Oct; 78(10):1312-7. PubMed ID: 16927284 [TBL] [Abstract][Full Text] [Related]
6. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients. Salzberger B; Däumer M; Gute P; Jaeger H; Knechten H; van Lunzen J; Mauss S; Mayr C; Moll A; Plettenberg A; Rockstroh J; Staszewski S; Stellbrink HJ; Stoll M; Sturmer M Eur J Med Res; 2007 Mar; 12(3):93-102. PubMed ID: 17507306 [TBL] [Abstract][Full Text] [Related]
7. Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide. Walmsley S; Henry K; Katlama C; Nelson M; Castagna A; Reynes J; Clotet B; Hui J; Salgo M; DeMasi R; Delehanty J J Infect Dis; 2003 Dec; 188(12):1827-33. PubMed ID: 14673761 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. de Requena DG; Bonora S; Castagna A; Hasson H; Marucco DA; D'Avolio A; Sciandra M; Trentini L; Calcagno A; Lazzarin A; Di Perri G J Antimicrob Chemother; 2008 Aug; 62(2):384-7. PubMed ID: 18487231 [TBL] [Abstract][Full Text] [Related]
9. Prognostic staging of extensively pretreated patients with advanced HIV-1 disease. Montaner J; Guimaraes D; Chung J; Gafoor Z; Salgo M; DeMasi R HIV Clin Trials; 2005; 6(6):281-90. PubMed ID: 16566082 [TBL] [Abstract][Full Text] [Related]
10. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. Reynes J; Arastéh K; Clotet B; Cohen C; Cooper DA; Delfraissy JF; Eron JJ; Henry K; Katlama C; Kuritzkes DR; Lalezari JP; Lange J; Lazzarin A; Montaner JS; Nelson M; O' Hearn M; Stellbrink HJ; Trottier B; Walmsley SL; Buss NE; Demasi R; Chung J; Donatacci L; Guimaraes D; Rowell L; Valentine A; Wilkinson M; Salgo MP AIDS Patient Care STDS; 2007 Aug; 21(8):533-43. PubMed ID: 17711378 [TBL] [Abstract][Full Text] [Related]
11. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. Nelson M; Arastéh K; Clotet B; Cooper DA; Henry K; Katlama C; Lalezari JP; Lazzarin A; Montaner JS; O'Hearn M; Piliero PJ; Reynes J; Trottier B; Walmsley SL; Cohen C; Eron JJ; Kuritzkes DR; Lange J; Stellbrink HJ; Delfraissy JF; Buss NE; Donatacci L; Wat C; Smiley L; Wilkinson M; Valentine A; Guimaraes D; Demasi R; Chung J; Salgo MP J Acquir Immune Defic Syndr; 2005 Dec; 40(4):404-12. PubMed ID: 16280694 [TBL] [Abstract][Full Text] [Related]
12. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study. Dwyer DE; Workman C; Hales G; Amin J; Cooper D; Miller J; Antivir Ther; 2006; 11(4):409-19. PubMed ID: 16856614 [TBL] [Abstract][Full Text] [Related]
13. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. Aquaro S; D'Arrigo R; Svicher V; Perri GD; Caputo SL; Visco-Comandini U; Santoro M; Bertoli A; Mazzotta F; Bonora S; Tozzi V; Bellagamba R; Zaccarelli M; Narciso P; Antinori A; Perno CF J Antimicrob Chemother; 2006 Oct; 58(4):714-22. PubMed ID: 16891628 [TBL] [Abstract][Full Text] [Related]
14. Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients. Ruof J; Dusek A; DeSpirito M; Demasi RA Clin Drug Investig; 2007; 27(7):469-79. PubMed ID: 17563127 [TBL] [Abstract][Full Text] [Related]
15. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Gripshover BM; Ribaudo H; Santana J; Gerber JG; Campbell TB; Hogg E; Jarocki B; Hammer SM; Kuritzkes DR; Antivir Ther; 2006; 11(5):619-23. PubMed ID: 16964830 [TBL] [Abstract][Full Text] [Related]
16. [Clinical efficacy and tolerance of enfuvirtide (Fuzeon), new antiretroviral inhibitors of intracellular penetration of human immunodeficiency virus (HIV) type 1]. Raffi F Med Mal Infect; 2004 Sep; 34 Spec No 1():8-17. PubMed ID: 15742550 [TBL] [Abstract][Full Text] [Related]
17. The suppression of immune activation during enfuvirtide-based salvage therapy is associated with reduced CCR5 expression and decreased concentrations of circulating interleukin-12 and IP-10 during 48 weeks of longitudinal follow-up. Carsenti-Dellamonica H; Saïdi H; Ticchioni M; Guillouet de Salvador F; Dufayard Cottalorda J; Garraffo R; Dellamonica P; Durant J; Gougeon ML HIV Med; 2011 Feb; 12(2):65-77. PubMed ID: 20500532 [TBL] [Abstract][Full Text] [Related]
18. Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients. Schapiro JM; Boucher CA; Kuritzkes DR; van de Vijver DA; Llibre JM; Lewis M; Simpson P; Delogne C; McFadyen L; Chapman D; Perros M; Valdez H; van der Ryst E; Westby M Antivir Ther; 2011; 16(3):395-404. PubMed ID: 21555822 [TBL] [Abstract][Full Text] [Related]
19. Clinical safety and efficacy of enfuvirtide (T-20), a new fusion inhibitor. A review of the presentation at the satellite symposium "New hope: advancing care in HIV infection" at the 15th annual Association of Nurses in AIDS Care conference, November 2002. Lalezari JP AIDS Read; 2003 Mar; 13(3 Suppl):S9-13. PubMed ID: 12765160 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. Gallien S; Braun J; Delaugerre C; Charreau I; Reynes J; Jeanblanc F; Verdon R; de Truchis P; May T; Madelaine-Chambrin I; Aboulker JP; Molina JM; J Antimicrob Chemother; 2011 Sep; 66(9):2099-106. PubMed ID: 21712241 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]